Search

everythinglearnresearchcommunity

for

Search:↓

3-Deoxysappanchalcone helps human hair cells grow and stimulates hair growth in mice by affecting certain cell signaling pathways.

Using neurohormones to control keratin can lead to new skin disease treatments.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

Stem cell technologies and regenerative medicine, including platelet-rich plasma, show promise for hair restoration in treating hair loss, but more research is needed.

Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.

Dupilumab helps children with alopecia areata regrow hair safely.

Recent advances in hair loss treatments show significant progress.

Blocking TSLP reduces skin inflammation and cell overgrowth in psoriasis.

New treatments for hair loss may target specific pathways and generate new hair follicles.

The research suggests that the ZP4 gene is linked to egg development in women with PCOS but requires more study to understand its role in infertility.

New markers and pathways have been found in skin tumors, helping better understand and diagnose them.

Mesenchymal stem cell therapy may help treat alopecia areata by promoting hair growth and reducing inflammation.

Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

MSC-EVs and UCB-EVs improve skin wound healing and reduce scarring.

Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Hair follicles can help diagnose traumatic brain injury quickly and non-invasively.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

Ruxolitinib treatment may cause eyelash growth.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Sebaceous glands are involved in various skin disorders, some treatable with medications like finasteride and minoxidil.

Some alopecia treatments might help treat COVID-19, but more research is needed.

Key genes linked to hair growth and cancer were identified in hairless mice.

Several new treatments for different types of hair loss show promise in improving patient quality of life.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.